Cost-Effectiveness and Dynamic Efficiency: Does the Solution Lie Within?

Value in Health

Volumn 20, Issue 2, 2017, Pages 240-243

  Refoios Camejo, Rodrigo ^a,b   Miraldo, Marisa ^c   Rutten, Frans ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

cost effectiveness; dynamic efficiency; pharmaceutical innovation; value framework

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; FUNDING; HEALTH CARE SYSTEM; HUMAN; PHARMACOECONOMICS; PRIORITY JOURNAL; ALGORITHM; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH STATUS; PURCHASING; QUALITY ADJUSTED LIFE YEAR;

PRESCRIPTION DRUG;

ALGORITHMS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH STATUS; PRESCRIPTION DRUGS; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; VALUE-BASED PURCHASING;

EID: 85013631852     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.12.004     Document Type: Article

References (10)

1. [1] le Polain, M., Franken, M., Koopmanschap, M., Cleemput, I., Drug reimbursement systems: international comparison and policy recommendations. KCE Reports, 2010, Belgian Health Care Knowledge Centre, Brussels, Belgium.
2. [2] Culyer, A., McCabe, C., Briggs, A., et al. Searching for a threshold, not setting one: the role of the National Institute of Health and Clinical Excellence. J Health Serv Res Policy 12 (2007), 56–58.
3. [3] National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. 2008, National Institute for Health and Clinical Excellence, London, UK.
4. [4] Kaló, Z., Annemans, L., Garrison, L., Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res 13 (2013), 735–741.
5. [5] Refoios Camejo, R., McGrath, C., Herings, R., A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness. Health Policy 100 (2011), 18–24.
6. [6] Refoios Camejo, R., McGrath, C., Herings, R., et al. Assessing the determinants of the potential for cost effectiveness over time: the empirical case of COPD. Value Health 16 (2013), 426–433.
7. [7] Refoios Camejo, R., McGrath, C., Miraldo, M., Rutten, F., The determinants of cost effectiveness potential: a historical perspective on lipid lowering therapies. Pharmacoeconomics 31 (2013), 445–454.
8. [8] Kanavos P, Manning J, Taylor D, et al. Implementing value-based price for pharmaceuticals in the UK. London, UK: 2020health.org, 2010.
9. [9] Medicines Pharmacy & Industry Group. A new value-based approach to the pricing of branded medicines - a consultation. 2010, Department of Health, Leeds, UK.
10. [10] Cook, J., Golec, J., Vernon, J., Pink, G., Real option value and path dependence in oncology innovation. Int J Econ Bus 18 (2011), 225–238.